The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Richard Rapoza

Showing 1-19 of 19 articles
Coronary interventions
Outcomes of optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation: one-year results from the ILUMIEN III: OPTIMIZE PCI trial
Ali Z, Karimi Galougahi K, Maehara A, Shlofmitz R, Fabbiocchi F, Guagliumi G, Alfonso F, Akasaka T, Matsumura M, Mintz G, Ben-Yehuda O, Zhang Z, Rapoza R, West N, Stone G
January 20, 2021 | 10.4244/EIJ-D-20-00498
Coronary interventions
Optical coherence tomography-guided coronary stent implantation compared to angiography: a multicentre randomised trial in PCI – design and rationale of ILUMIEN IV: OPTIMAL PCI
Ali Z, Landmesser U, Karimi Galougahi K, Maehara A, Matsumura M, Shlofmitz R, Guagliumi G, Price M, Hill J, Akasaka T, Prati F, Bezerra H, Wijns W, Mintz G, Ben-Yehuda O, McGreevy R, Zhang Z, Rapoza R, West N, Stone G
January 20, 2021 | 10.4244/EIJ-D-20-00501
Coronary interventions
Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial
Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Rapoza R, West N, Reith S, de Sousa Almeida M, Campo G, Iniguez-Romo A, Serruys P
December 4, 2020 | 10.4244/EIJ-D-20-00024
Coronary interventions
Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial
Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, Ueno T, Ando K, Furuya J, Igarashi K, Kozuma K, Tanabe K, Kusano H, Rapoza R, Popma J, Stone G, Simonton C, Serruys P, Kimura T
October 20, 2016 | 10.4244/EIJY16M09_01
Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data
Bourantas C, Serruys P, Nakatani S, Zhang Y-J, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns R, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia H
November 20, 2015 | 10.4244/EIJY14M10_06
Coronary interventions
Technology limitations of BRS in bifurcations
Fox J, Hossainy S, Rapoza R, Serruys P
May 19, 2015 | 10.4244/EIJV11SVA38
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial
Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P
March 20, 2015 | 10.4244/EIJY14M04_11
Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model
Vorpahl M, Nakano M, Perkins L, Otsuka M, Jones R, Acampado E, Lane J, Rapoza R, Kolodgie F, Virmani R
November 20, 2014 | 10.4244/EIJV10I7A143
Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J
March 20, 2014 | 10.4244/EIJV9I11A217
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P
October 25, 2013 | 10.4244/EIJV9I6A115
Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial
Brugaletta S, Gomez-Lara J, Bruining N, Radu M, van Geuns R, Thuesen L, McClean D, Koolen J, Windecker S, Whitbourn R, Oberhauser J, Rapoza R, Ormiston J, Garcia-Garcia H, Serruys P
July 27, 2012 | 10.4244/EIJV8I3A54
Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study
Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston J, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia H, Serruys P
June 27, 2012
In vivo visualisation by three-dimensional optical coherence tomography of stress crazing of a bioresorbable vascular scaffold implanted for treatment of human coronary stenosis
Radu M, Onuma Y, Rapoza R, Diletti R, Serruys P
April 20, 2012 | 10.4244/EIJV7I12A227
In vivo characterisation of bioresorbable vascular scaffold strut interfaces using optical coherence tomography with Gaussian line spread function analysis
Sheehy A, Gutiérrez-Chico J-L, Diletti R, Oberhauser J, Glauser T, Harrington J, Kossuth M, Rapoza R, Onuma Y, Serruys P
February 21, 2012 | 10.4244/EIJV7I10A195
Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application
Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, Gogas B, van Geuns R, Regar E, Schultz C, Windecker S, Lefèvre T, Brueren B, Powers J, Perkins L, Rapoza R, Virmani R, Garcia-Garcia H, Serruys P
July 29, 2011 | 10.4244/EIJV7I3A64
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study
Brugaletta S, Garcia-Garcia H, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin E, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston J, Serruys P
April 20, 2011
Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial
Onuma Y, Serruys P, Ormiston J, Regar E, Webster M, Thuesen L, Dudek D, Veldhof S, Rapoza R
September 30, 2010
In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial
Okamura T, Garg S, Gutiérrez-Chico J-L, Shin E, Onuma Y, Garcia-Garcia H, Rapoza R, Sudhir K, Regar E, Serruys P
April 12, 2010
Design principles and performance of bioresorbable polymeric vascular scaffolds
Oberhauser J, Hossainy S, Rapoza R
December 30, 2009

Latest news

NEW ISSUE
State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more
October 20, 2021
STATE OF THE ART
Valve-in-valve TAVI: a practical overview
Giuseppe Tarantini et al.
October 20, 2021
AHEAD OF PRINT
TAVI in younger (<70 years old) patients: the AMTRAC registry
Guy Witberg et al.
October 22, 2021
AHEAD OF PRINT
Impact of LVOT calcification in transfemoral TAVI patients
L. Waldschmidt et al.
October 19, 2021
VIEWPOINT
My Stroke Story
Marco Noc
October 20, 2021
AHEAD OF PRINT
Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial
Hironori Hara et al.
October 22, 2021
AHEAD OF PRINT
Serum caffeine causes adenosine-induced FFR overestimation
Hideaki Tanaka et al.
October 15, 2021
Coronary
Valvular disease
Heart failure
Peripheral
Hypertension
Stroke